MedPage Today on MSN

Practice-Changing Trial in Prostate Cancer Shows Benefits of Perioperative Therapy

ADT plus apalutamide before and after surgery significantly improved metastasis-free survi ...

J&J drug Erleada reduces risk of prostate cancer spread, death

Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and ...
Healio

‘Thrilling’: Regimen reduces metastasis, recurrence in high-risk prostate cancer

The addition of apalutamide to androgen deprivation therapy before and after surgery improved outcomes among men with ...

J&J study suggests earlier use of prostate cancer drug improves outcomes

Johnson & Johnson’s PROTEUS Phase 3 trial shows apalutamide + hormone therapy before/after surgery improves outcomes in ...
SurvivorNet on MSN

ASCO 2026: A major prostate cancer trial shows drug can keep high-risk disease from returning for longer

Data from the PROTEUS trial showed that adding a hormone-blocking pill called apalutamide to standard hormone therapy, both ...
Morningstar

New FDA-Cleared At-Home Treatment Helps Men Regain Bladder Control After Prostate Surgery

NEWTOWN, Conn., March 31, 2026 /PRNewswire/ -- Elidah today announced FDA clearance of Elitone for Men, a non-invasive, at-home treatment designed to help men regain bladder control after prostate ...
Medical Xpress

Hormone therapy may not benefit most men receiving radiotherapy after prostate surgery, study finds

A new study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that adding hormone therapy to postoperative radiotherapy may provide little survival benefit for most men ...

Blood test spots failing prostate cancer treatment within 6-12 weeks, study finds

A new blood test could help doctors identify whether a treatment for advanced prostate cancer is failing weeks earlier than current tests, according to a U.K.-wide study led by UCL researchers. The ...